Table 1.
Expression of GSK-3α/β in epithelial ovarian cancer and benign ovarian tumor
| Parameters | GSK-3α/β immunostaining
|
z | P-value | |||
|---|---|---|---|---|---|---|
| − | + | ++ | +++ | |||
| Benign or malignant | −5.956 | <0.001 | ||||
| Benign tumor (n=20) | 18 | 2 | 0 | 0 | ||
| EOC (n=71) | 8 | 21 | 19 | 23 | ||
| Age of EOC patient (years) | −0.222 | 0.824 | ||||
| ≤50 (n=38) | 3 | 13 | 11 | 11 | ||
| >50 (n=33) | 5 | 8 | 8 | 12 | ||
| Stage of EOC | −3.328 | 0.001 | ||||
| FIGO I + II (n=27) | 5 | 11 | 9 | 2 | ||
| FIGO III + IV (n=44) | 3 | 10 | 10 | 21 | ||
| Residual tumor of EOC | −1.406 | 0.160 | ||||
| ≤1 cm (n=53) | 8 | 15 | 15 | 15 | ||
| >1 cm (n=18) | 0 | 6 | 4 | 8 | ||
| Histological type of EOC | −0.078 | 0.938 | ||||
| Serous (n=39) | 3 | 14 | 9 | 13 | ||
| Other (n=32) | 5 | 7 | 10 | 10 | ||
| Histological grade of EOC | −1.552 | 0.121 | ||||
| Grade 1 (n=11) | 1 | 5 | 5 | 0 | ||
| Grade 2 + 3 (n=60) | 7 | 16 | 14 | 23 | ||
| Serum CA125 of EOC patient (U/mL) | −2.053 | 0.040 | ||||
| ≤500 (n=47) | 8 | 15 | 11 | 13 | ||
| >500 (n=24) | 0 | 6 | 8 | 10 | ||
| Chemotherapy response of EOC | −1.234 | 0.217 | ||||
| Response (n=55) | 6 | 19 | 14 | 16 | ||
| Nonresponse (n=16) | 2 | 2 | 5 | 7 | ||
Abbreviations: CA125, cancer antigen 125; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; GSK, glycogen synthase kinase.